| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Setrusumab | UX143; NOV-3; MOR-05813; BPS-804 | Phase 3 Clinical | Morphosys Ag, Novartis Pharma Ag | Bone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic | Details |
| AGA-2115 | AGA2115; AGA-2115 | Phase 2 Clinical | Angitia Biopharmaceuticals (Guangzhou) Ltd | Osteogenesis Imperfecta | Details |
| AGA-2118 | AGA-2118 | Phase 2 Clinical | Angitia Biomedicines Ltd | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Resugosbart | SHR-1222 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Romosozumab biosimilar(Zhuhai Federation Biomedicine) | Phase 1 Clinical | Zhuhai Federation Biomedicine Co Ltd | Osteoporosis, Postmenopausal | Details | |
| Blosozumab | TST002; LY-2541546; TST002-IgG4 | Phase 1 Clinical | Eli Lilly And Company | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Romosozumab | CDP-7851; AMG-785 | Approved | Evenity, EVENITY | Japan | Osteoporosis | Amgen Inc | 2019-01-08 | Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal | Details |